Evaluation of Efficacy and Safety in Control Cough and the Relief of Nasal Symptoms in Children 2-12 Years Old,Suffering From Cough and Acute Rhinitis
Withdrawn
Ache Laboratorios Farmaceuticos S.A.
Phase 3
2011-10-01
Multicenter clinical trial, phase III, controlled by active medicine, open, randomized,
enroll 962 children, 2 to 12 years old, that suffer acute inflammation upper airway
characterized by non-productive cough, daytime/nighttime, with duration for at least 3 and no
more than 5 consecutive days (without systemic/topic use of medication during this period)
followed by nasal congestion, with or without associate other nasal symptoms (sneezing, runny
nose, nasal itching and/or mouth breathing). The subjects will be allocated in 2 parallel
groups, and will receive the medicines of study, according of the randomization.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
